Sasse's Cancer Drug Breakthrough Gains Momentum
Ben Sasse credits 'miracle' drug daraxonrasib after 76% tumor shrinkage; NEJM study, FDA has expanded access.
As featured on
More than 130 studies focused on such efforts were presented at the American Society of Clinical Oncology meeting in Chicago this month.
